+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
ID05672901

Comparing Silicone Gel and Estrogen Vaginal Cream to Treat Genitourinary Syndrome of Menopause

Led by Stratpharma AG · Updated on 2026-02-20

100

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of StrataMGT, a silicone gel, compared to estrogen vaginal cream in managing Genitourinary Syndrome of Menopause GSM. The main goal is to see if StrataMGT is not worse than standard estrogen treatment in improving quality of life for women experiencing GSM. This is a randomized controlled trial sponsored by Stratpharma AG. Participants will be randomly assigned to one of two groups. One group will use StrataMGT, applying the silicone gel 2 to 5 times daily without a limit on application frequency, for three consecutive months. The other group will use Estrace vaginal cream, starting with 1 gram daily for two weeks, then switching to a maintenance dose of 1 gram three times a week for the same duration. These treatments are being studied to compare their effects on symptoms and quality of life. During the study, participants will be assessed monthly for three months. Researchers will monitor quality of life, clinical signs, symptoms, visual pathology, and any adverse reactions. Patient-reported outcome measures including symptoms, dyspareunia, product rating, and treatment adherence will also be collected. These evaluations will help determine how each treatment affects the participants over the study period.

CONDITIONS

Brief Title

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here